Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Aeterna Zentaris (AEZS)

Aeterna Zentaris (AEZS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Aeterna Zentaris 222 BAY STREET SUITE 3000 PO BOX 53 TORONTO A6 M5K 1E7 CAN

www.zentaris.com P: 49-6942-6020

Description:

AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers.

Key Statistics

Overview:

Market Capitalization, $K 8,014
Enterprise Value, $K -26,006
Shares Outstanding, K 1,214
Annual Sales, $ 4,500 K
Annual Net Income, $ -16,550 K
Last Quarter Sales, $ 120 K
Last Quarter Net Income, $ -5,630 K
EBIT, $ -18,020 K
EBITDA, $ -19,460 K
60-Month Beta 1.60
% of Insider Shareholders 0.10%
% of Institutional Shareholders 0.73%
Float, K 1,213
% Float 99.90%
Short Volume Ratio 0.46

Growth:

1-Year Return -43.27%
3-Year Return -92.73%
5-Year Return -97.61%
5-Year Revenue Growth -83.26%
5-Year Earnings Growth -154.56%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -4.74 on 05/14/24
Next Earnings Date N/A
Earnings Per Share ttm -13.64
EPS Growth vs. Prev Qtr -2.16%
EPS Growth vs. Prev Year -34.66%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-4 on 05/03/24

AEZS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -83.45%
Return-on-Assets % -45.76%
Profit Margin % -367.78%
Debt/Equity 0.00
Price/Sales 1.79
Price/Cash Flow N/A
Price/Book 0.62
Book Value/Share 15.04
Interest Coverage -1,654.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar